Abemaciclib

Evidence Level: N/A Predicted Indications: 0

Table of Contents

  1. Abemaciclib
    1. Pharmacist Assessment Report
    2. Abemaciclib
    3. Summary
    4. Quick overview
    5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
    6. Australia Market Information
    7. Cytotoxicity
    8. Safety Considerations
    9. Disclaimer

Pharmacist Assessment Report

Abemaciclib

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Abemaciclib, so there is currently no new predicted indication. The drug’s recorded uses are listed below. These are the drug’s own recorded uses, not model candidates.

Quick overview

Item Content
Known uses recorded for this drug 1
Australia Market Status Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items 1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication Source
breast neoplasms licence in another country
Indication Approved category
none none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence Product Dosage form Status
11868P Verzenio Tablet 150 mg Valid

Cytotoxicity

Item Content
Cytotoxicity Classification Targeted therapy (CDK4/6 kinase inhibitor)
Myelosuppression Risk Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification Please refer to the Product Information (PI) warnings and precautions
Monitoring Items Please refer to the PI; typically includes FBC, liver function and renal function
Handling Protection Please refer to the PI and local cytotoxic drug handling policies

Safety Considerations

Label warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these.

Drug Interactions: 100 interactions were recorded in total; 20 are shown in the data compiled. Major-level interactions include:

  • Clarithromycin
  • Cobicistat
  • Deferiprone
  • Samarium (153Sm) lexidronam
  • Lumacaftor

Moderate-level interactions include aprepitant, clotrimazole, dexamethasone, metformin, metreleptin, naltrexone, troglitazone, deferasirox, palifermin, strontium chloride Sr-89, ticagrelor, roflumilast, chloramphenicol, erythromycin and fluconazole.

Other safety signals from the literature: Pharmacovigilance and review articles describe cardiovascular concerns with CDK4/6 inhibitors, including QTc prolongation, thromboembolic events and atrial arrhythmia, as well as reports of kidney injury with abemaciclib.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

This site uses Just the Docs, a documentation theme for Jekyll.